- Home
- AGAE vs TCRX Comparison
AGAE vs TCRX Comparison
Compare AGAE & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- TCRX
- Stock Information
- Founded
- AGAE 2017
- TCRX 2018
- Country
- AGAE United States
- TCRX United States
- Employees
- AGAE N/A
- TCRX N/A
- Industry
- AGAE Cable & Other Pay Television Services
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- AGAE Telecommunications
- TCRX Health Care
- Exchange
- AGAE Nasdaq
- TCRX Nasdaq
- Market Cap
- AGAE 84.7M
- TCRX 90.5M
- IPO Year
- AGAE N/A
- TCRX 2021
- Fundamental
- Price
- AGAE $3.01
- TCRX $1.45
- Analyst Decision
- AGAE
- TCRX Strong Buy
- Analyst Count
- AGAE 0
- TCRX 6
- Target Price
- AGAE N/A
- TCRX $9.50
- AVG Volume (30 Days)
- AGAE 646.6K
- TCRX 774.8K
- Earning Date
- AGAE 06-06-2025
- TCRX 05-06-2025
- Dividend Yield
- AGAE N/A
- TCRX N/A
- EPS Growth
- AGAE N/A
- TCRX N/A
- EPS
- AGAE N/A
- TCRX N/A
- Revenue
- AGAE $9,256,023.00
- TCRX $4,421,000.00
- Revenue This Year
- AGAE N/A
- TCRX $68.86
- Revenue Next Year
- AGAE N/A
- TCRX $14.01
- P/E Ratio
- AGAE N/A
- TCRX N/A
- Revenue Growth
- AGAE 36.15
- TCRX N/A
- 52 Week Low
- AGAE $0.66
- TCRX $1.02
- 52 Week High
- AGAE $3.79
- TCRX $9.29
- Technical
- Relative Strength Index (RSI)
- AGAE 70.08
- TCRX 49.42
- Support Level
- AGAE $1.77
- TCRX $1.33
- Resistance Level
- AGAE $3.79
- TCRX $1.49
- Average True Range (ATR)
- AGAE 0.48
- TCRX 0.11
- MACD
- AGAE 0.12
- TCRX 0.02
- Stochastic Oscillator
- AGAE 66.67
- TCRX 69.12
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.